Table 1 The clinical and pathological characteristics of MANEC in the gastric and ampullary

Age, years, median (range)

59.5 (48–74)

Sex, male/female, n

26/6

AFP, ng/ml, median (range)

3.23 (1.04–64.65)

AFP > 20 ng/ml, n (%)

2 (6.2%)

CA19-9, U/ml, median (range)

12.82 (0.91–866.8)

CA19-9 > 40 U/ml, n (%)

5 (15.6%)

CEA, ng/ml, median (range)

3.12 (0.93–86.67)

CEA > 8 ng/ml, n (%)

5 (15.6%)

Tumor location, n

 Ampulla of Vater

7

 Stomach

25

Tumor size < 3 cm/>3 cm

14/18

T, n (%)

 T1

1 (3.1%)

 T2

6 (18.8%)

 T3

16 (50.0%)

 T4

9 (28.1%)

Lymph node metastasis, n (%)

24(75.0%)

TNM stage*, n (%)

 I

2(15.6%)

 II

5 (15.6%)

 III

24 (65.7%)

 IV

1 (3.1%)

Ki67 median (range)

50.0% (10.0–90.0%)

Cell type of NEC, n (%)

 Large cell

11 (34.4%)

 Mixed cell

14 (43.8%)

 Small cell

7 (21.8%)

Lymphatic invasion yes/no

27/5

Angioinvasion yes/no

18/14

Perineural invasion yes/no

20/12

Differentiation of adenocarcinoma, n (%)

 Well differentiation

3 (9.3%)

 Moderate differentiation

12 (37.5%)

 Poor differentiation

10 (31.3%)

Signet ring cell/Mucin

7 (21.9%)

Syn (+), n (%)

31 (96.9%)

CgA (+), n (%)

26 (81.3%)

CD56 (+), n (%)

18(56.3%)

EMA(+), n (%)

11 (34.4%)

PCK(+), n (%)

18 (56.3%)

CK7(+), n (%)

8 (25.0%)

Chemotherapy, n (%)

11 (34.4%)